Denmark's Genmab hits the jackpot with $500M+ US IPO as smaller biotechs rake in a combined $147M
Danish drugmaker Genmab A/S is off to the races with perhaps one of the biggest biotech public listings in decades, having reaped over $500 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
